PUNE, India, December 16, 2015 /PRNewswire/ --
This report provides comprehensive information on the therapeutic development for Spinal cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
The research reviews key players involved in the therapeutic development for Spinal cord Injury and special features on late-stage and discontinued projects. Complete report on H2 2015 pipeline review of Spinal Cord Injury with 60 market data tables and 15 figures, spread across 225 pages is available at http://www.rnrmarketresearch.com/spinal-cord-injury-pipeline-review-h2-2015-market-report.html .
The report also reviews key players involved in the therapeutic development for Spinal Cord Injury and special features on late-stage and discontinued projects. Companies discussed in this Spinal Cord Injury - Pipeline Review, H2 2015 report include Acorda Therapeutics, Inc., Asubio Pharma Co., Ltd., Athersys, Inc., Axerion Therapeutics, Inc., BioArctic Neuroscience AB, Cortex Pharmaceuticals, Inc., Faron Pharmaceuticals Oy, FirstString Research, Inc., Genervon Biopharmaceuticals, LLC, Grupo Ferrer Internacional, S.A., Hemostemix Ltd, Histocell S.L., K-Stemcell Co., Ltd., Kadimastem Ltd., Kringle Pharma, Inc., Lipopharma Therapeutics SL, Lpath, Inc., MandalMed, Inc., Mapreg S.A.S., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neuronax SAS, Omeros Corporation, PharmatrophiX, Inc., Pharmicell Co., Ltd., Q Therapeutics, Inc., Quark Pharmaceuticals, Inc., Remedy Pharmaceuticals, Inc., RhinoCyte, Inc., SanBio, Inc., Sirnaomics, Inc., StemCells, Inc., Stemedica Cell Technologies, Inc., TissueGene, Inc., Vertex Pharmaceuticals Incorporated and Vicore Pharma AB.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Drug Profiles mentioned in this report are (buspirone + levodopa + carbidopa), ACTX-08, Antibody to Inhibit RGM for Spinal Cord Injury, AP-325, AST-OPC-1, Astrostem, AX-007, BA-277, BA-434, C-21, Cell Therapy for Spinal Cord Injury, Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury, Cerecellgram-Spine, CHEC-7, CHEC-9, chondroitinase ABC nanosphere, cimaglermin alfa, CLR-01, CM-101, CX-1739, CX-717, Drug for Spinal Cord Injury, Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury, FIB-117, glyburide, GM-603, HBN-1, HC-016, HuCNS-SC, ICCN-100, IMS-001, IMS-002, interferon beta-1a, KP-100IT, LM11A-31, LPA-181, Lpathomab, MAP-4343, MultiStem, NCP-01, Neural Stem Cells, neurovitas, NgR(310)ecto-Fc, NSI-566, NX-210, Oligonucleotide for Central Nervous System and Metabolic Disorders, Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury, Peptides for Central Nervous System and Musculoskeletal Disorders, PT-00114, Q-Cells, Recombinant Protein for Spinal Cord Injury, SB-618, SB-623, SC-0806, siRNA for CNS Disorders, Small Molecule to Antagonize GPR17 for Central Nervous System Disorders, Small Molecules for Spinal Cord Injury, Stem Cell Therapy for Acute Spinal Cord Injury, Stem Cell Therapy for CNS Disorders, Stem Cell Therapy for Neurodegenerative Disorders, Stem Cell Therapy for Spinal Cord Injury, Stem Cell Therapy for Spinal Cord Injury, Stem Cell Therapy Program for Neurodegenerative Diseases, STP-805, SUN-13837, Synthetic Peptide for Spinal Cord Injuries, Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury, Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease, Tenascin-C Fragments for Spinal Cord Injury, TG-N, UH-0113, UH-0213 and VX-210. Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=419698 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities with key players involved in the therapeutics development for Spinal Cord Injury and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects, review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Explore more reports on Central Nervous System (CNS) therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
SOURCE RnR Market Research